SIR Publishers
CENTER FOR INTERNATIONAL SCIENTIFIC PUBLICATIONS
JOURNAL OF NURSING AND WOMEN'S HEALTH
ISSN(Online): 2984-8083
Volume-9, Issue-01, Published |16-01-2026|

CORRELATION OF ADAMTS-5 LEVEL WITH CLINICAL SYMPTOMS AND DISEASE STAGES IN KNEE OSTEOARTHRITIS

O‘ralova Gulshoda Eshnazar qizi
Student of the Faculty of Medicine,
Termiz Unversity of Economics and Service
Termiz University of Economics and Service,
Faculty of Medicine, Lecturer of Clinical Medical Sciences
Shermatov Kholbek Fakhritdinovich
shermatovxolbek8@gmail.com

ABSTRACT

Knee osteoarthritis is the most common degenerative joint disease and a leading cause of chronic pain, mobility limitation, and reduced quality of life in adults and older people. Radiographic staging remains practical in routine care, but structural severity on imaging does not always correspond to pain intensity or functional loss. This clinical mismatch has increased interest in biochemical markers that reflect active tissue damage. ADAMTS-5, a major aggrecanase involved in cartilage matrix degradation, is a biologically plausible candidate marker for evaluating disease activity in knee osteoarthritis. The manuscript presents an analytical cross-sectional study framework with patient selection criteria, symptom assessment tools, radiographic grading, biomarker measurement principles, and statistical methods for correlation and regression analysis. It also discusses expected findings, common confounders, and limitations of biomarker-based interpretation. ADAMTS-5 is best considered a complementary indicator rather than a stand-alone diagnostic test. If confirmed in larger longitudinal cohorts, ADAMTS-5 profiling may improve patient phenotyping, progression risk assessment, and treatment monitoring in knee osteoarthritis.

Keywords: Knee osteoarthritis, ADAMTS-5, aggrecanase, biomarker, cartilage degradation, Kellgren-Lawrence stage, pain, WOMAC.

INTRODUCTION

Knee osteoarthritis is a chronic, progressive, and heterogeneous disorder involving the entire joint organ rather than cartilage alone. The disease affects articular cartilage, subchondral bone, synovium, menisci, ligaments, and periarticular muscles. Patients commonly report activity-related pain, short morning stiffness, crepitus, gradual loss of function, and difficulty performing everyday tasks such as walking long distances, climbing stairs, squatting, or standing up from a chair. Because disease progression is slow and variable, patients with apparently similar radiographic findings may have very different symptom severity and disability.

Conventional radiography, especially the Kellgren-Lawrence classification, is widely used to stage knee osteoarthritis and remains clinically useful because it is inexpensive and available. However, radiographs mainly capture relatively late structural outcomes such as joint-space narrowing, osteophytes, sclerosis, and deformity. They do not directly show early molecular events in cartilage matrix breakdown. This is one reason why radiographic stage and patient symptoms often correlate only modestly. The need for biomarkers that reflect ongoing pathological activity has therefore become a central issue in osteoarthritis research.


ADAMTS-5 (A Disintegrin and Metalloproteinase with Thrombospondin Motifs-5) is one of the principal enzymes responsible for cleavage of aggrecan, a key proteoglycan that provides cartilage with hydration and compressive resistance. Aggrecan loss is an early and functionally critical step in cartilage degeneration. Once aggrecan is depleted, the tissue becomes less resilient and more vulnerable to irreversible structural damage. Mechanical overload, inflammatory cytokines, and


SIR Publishers
CENTER FOR INTERNATIONAL SCIENTIFIC PUBLICATIONS
JOURNAL OF NURSING AND WOMEN'S HEALTH
ISSN(Online): 2984-8083
Volume-9, Issue-01, Published |16-01-2026|

altered chondrocyte signaling may increase ADAMTS-5 expression, linking joint stress to matrix destruction.

From a clinical perspective, ADAMTS-5 is attractive because it may capture a biologically active phase of disease that is not fully reflected by imaging alone. If elevated ADAMTS-5 is associated with greater pain, poorer function, or advanced radiographic stage, the marker could support patient stratification and follow-up. At the same time, osteoarthritis symptoms are multifactorial, and no single biomarker can explain all clinical variability. The usefulness of ADAMTS-5 therefore depends on whether it adds meaningful information beyond standard assessment tools.

The aim of this article is to provide an English-language IMRAD-style academic sample on the topic of the correlation between ADAMTS-5 level, clinical symptoms, and disease stage in knee osteoarthritis. The text is written in an original scholarly style and is intended as a ready template for coursework, thesis drafting, or adaptation to real clinical data. Illustrative figures are included for explanation and should be replaced with actual study outputs in formal submission.





MATERIALS AND METHODS

Study design and setting. A cross-sectional analytical study design is suitable for evaluating the association between ADAMTS-5 level and both clinical and radiographic characteristics in knee osteoarthritis. Patients may be recruited consecutively from rheumatology or orthopedic outpatient

clinics. This design allows efficient assessment of biomarker-clinical relationships in a real-world symptomatic population and can serve as a foundation for later prospective studies.

Participants. Adults with primary knee osteoarthritis are enrolled after informed consent. Inclusion criteria may include age above 40 years, chronic knee pain lasting at least three months, and radiographic evidence consistent with osteoarthritis. Exclusion criteria should minimize confounding and may include inflammatory arthritis, gout or pseudogout, acute infection, recent intra-articular steroid injection, recent major trauma or surgery, severe systemic illness, and active malignancy. When bilateral disease is present, a predefined rule should identify the index knee for analysis.

Clinical assessment. Pain severity is measured using a Visual Analogue Scale (VAS) or Numeric Rating Scale. Functional status is assessed using a validated questionnaire such as WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index) or KOOS. Additional variables include morning stiffness duration, walking distance limitation, stair-climbing difficulty, analgesic use, symptom duration, and previous conservative treatment. Body mass index is recorded because obesity is a major mechanical and inflammatory contributor to disease severity.

Radiographic assessment. Standard weight-bearing anteroposterior and lateral knee radiographs are obtained and graded according to the Kellgren-Lawrence system (grades I-IV). To improve reliability, two trained readers independently score radiographs and resolve discrepancies by consensus. If available, supplemental structural measures such as joint-space width or osteophyte scoring may be included for more detailed analysis.

Biomarker measurement. Peripheral venous blood is collected under standardized conditions, ideally at similar times of day to reduce pre-analytical variability. Serum is separated, aliquoted, and stored appropriately until analysis. ADAMTS-5 concentration is measured using a validated ELISA kit according to manufacturer instructions. Samples should be run in duplicate, with calibration curves and internal controls. Where resources permit, additional biomarkers (for example CRP, COMP, or inflammatory cytokines) may be measured to explore combined models and confounding effects.

Statistical analysis. Data are summarized using mean and standard deviation for normally distributed variables or median and interquartile range for non-normal variables. Group comparisons across Kellgren-Lawrence stages are performed using ANOVA or Kruskal-Wallis tests as appropriate. Correlations between ADAMTS-5 and symptom scores are assessed using Pearson or Spearman methods. Multivariable regression models are recommended to adjust for age, sex, body mass index, symptom duration, and inflammatory markers. Significance thresholds and confidence intervals should be reported clearly, and effect size interpretation should accompany p values.

Ethics. The protocol should be approved by an institutional ethics committee. All participants must provide informed consent, and confidentiality of clinical and laboratory data should be maintained throughout the study.

RESULTS


In a typical symptomatic knee osteoarthritis cohort, ADAMTS-5 concentrations are expected to show considerable inter-individual variability. This variability reflects biological heterogeneity, differences in disease activity, obesity burden, inflammatory status, and medication use. For that reason, interpretation should focus not only on absolute values but also on distribution patterns, stage-wise comparisons, and adjusted associations with symptoms.

A common hypothesis is that mean ADAMTS-5 level increases across radiographic stages, with lower values in early Kellgren-Lawrence grades and higher values in advanced grades. The trend may not be perfectly linear, and overlap between stages is expected. Such overlap does not make the

biomarker useless; rather, it indicates that ADAMTS-5 may be more informative for identifying active matrix degradation than for assigning a strict radiographic category on its own.

With respect to symptoms, ADAMTS-5 may show a positive correlation with pain intensity and a stronger correlation with composite functional limitation scores. Functional scores often integrate pain, stiffness, and mechanical impairment, making them more sensitive to cumulative disease burden than single-item pain ratings. In adjusted models, the association may weaken but remain statistically meaningful after accounting for body mass index, age, sex, and inflammatory markers.

It is also plausible that subgroup differences emerge. For example, patients with shorter disease duration may demonstrate a clearer ADAMTS-5 signal if active cartilage breakdown is more prominent earlier in progression. Conversely, in end-stage disease, severe structural damage and chronic pain mechanisms may reduce the strength of biomarker-symptom correlation even when biomarker values remain elevated.



JOURNAL OF NURSING AND WOMEN'S HEALTH
ISSN(Online): 2984-8083
Volume-9, Issue-01, Published |16-01-2026|

Figure 3. Illustrative increase in ADAMTS-5 across radiographic OA stages




Figure 3. Illustrative stage-wise comparison of mean ADAMTS-5 level across Kellgren-Lawrence grades (example visualization, not real patient data).

The illustrative figures above are included to model how results may be presented in an academic manuscript. In a real study, exact sample size per stage, confidence intervals, test statistics, and adjusted regression coefficients should be reported. Tables may also summarize demographic and clinical characteristics to help interpret the observed associations.

Overall, the expected analytical conclusion from such a dataset would be that higher ADAMTS-5 levels are associated with a greater burden of symptoms and more advanced structural disease, while acknowledging that the magnitude of association is moderate and influenced by multiple confounding variables.

DISCUSSION

The biological rationale for linking ADAMTS-5 to knee osteoarthritis severity is strong. ADAMTS-5 is a key aggrecanase, and aggrecan depletion is one of the earliest critical events in cartilage degeneration. Increased ADAMTS-5 activity is therefore mechanistically compatible with accelerated matrix damage, loss of cartilage resilience, and progressive joint dysfunction. This makes the biomarker particularly relevant for studies seeking to connect molecular pathology with clinical presentation.

However, symptom severity in osteoarthritis cannot be explained by cartilage breakdown alone. Articular cartilage is aneural, and pain may originate from synovium, subchondral bone, menisci, periarticular structures, and central pain processing mechanisms. As a result, a moderate correlation between ADAMTS-5 and pain is not a limitation but a realistic reflection of disease complexity. Biomarker interpretation is most meaningful when integrated with symptom scales, examination findings, and imaging results.

An important clinical implication is the potential use of ADAMTS-5 for phenotyping. Patients within the same Kellgren-Lawrence stage may differ substantially in ongoing catabolic activity. A biomarker profile that includes ADAMTS-5 could help identify individuals with more active matrix

degradation, who may be at higher risk of progression or may respond differently to interventions targeting inflammation, mechanical load, or tissue catabolism.

Methodological standardization remains essential. Differences in sample collection time, storage conditions, assay platforms, and laboratory quality control can affect measured concentrations and limit comparability across studies. Clinical factors such as obesity, metabolic comorbidity, analgesic use, and bilateral disease further complicate interpretation. Future research should therefore prioritize standardized protocols, multicenter validation, and transparent reporting of pre-analytical and analytical procedures.

Longitudinal studies are especially important. A single cross-sectional measurement can demonstrate association but not temporal prediction. Repeated biomarker assessment over time, combined with symptom trajectories and radiographic or MRI progression, would clarify whether ADAMTS-5 has value as a prognostic marker and whether changes in ADAMTS-5 track treatment response. Multi-marker panels may also outperform any single biomarker in predicting progression or clinical outcomes.

This manuscript is intentionally presented as an original, human-readable sample article. For journal submission or thesis defense, the author should replace the illustrative graphics and generalized results with real patient data, exact statistical outputs, ethics approval information, and institution-specific details. Doing so will transform the present template into a fully evidence-based manuscript ready for formal review.

CONCLUSION

ADAMTS-5 is a biologically meaningful candidate biomarker in knee osteoarthritis because it directly participates in aggrecan degradation and cartilage matrix injury. Mechanistic evidence and clinical reasoning support a likely positive association between higher ADAMTS-5 levels, greater symptom burden, and more advanced radiographic stage, although the strength of these relationships varies across populations and study designs. In practice, ADAMTS-5 should be interpreted as a complementary marker that may improve disease phenotyping and monitoring when combined with clinical assessment and imaging. Well-designed longitudinal studies with standardized laboratory methods are required to define its prognostic value and its practical role in precision management of knee osteoarthritis.

REFERENCES

1. Yakubov DZh, Gaybullaev ShO. The diagnostic importance of radiation diagnostic methods in determining the degree of expression of gonarthrosis. Uzbek Journal of Case Reports. 2022;2(1):36-40. doi:10.55620/ujcr.2.1.2022.7.
2. Umarkulov ZZ, Mamasoliev BM. Influence of post-traumatic chondropathy on the functional state of the knee joints in athletes. Uzbek Journal of Case Reports. 2022;2(1):31-35. doi:10.55620/ujcr.2.1.2022.6.
3. Avezova ShSh, Madumarova ZSh, Zulunov AT, Yakubov NI. Comprehensive radiation diagnosis of osteoarthrosis of the knee joint in the early stages. Web of Medicine: Journal of Medicine, Practice and Nursing. 2024;2(3):132-136.
4. Avezova ShSh, Madumarova ZSh, Zulunov AT, Yakubov NI. Comprehensive radiographic assessment of early-stage osteoarthritis of the knee joint. Web of Medicine: Journal of Medicine, Practice and Nursing. 2025;3(6):269-272.
5. Mamadaliyeva MA, Pulatova ShB. Effectiveness of traditional medicine treatments in osteoarthritis of the knee joint. Web of Medicine: Journal of Medicine, Practice and Nursing. 2025;3(1):202-208.

6. Safarov AJ, Akhmedova DS. Osteoarthritis disease and its rehabilitation. Western European Journal of Medicine and Medical Science. 2024;2(4):37-42.

7. Madrakhimov S, Karimov M. Patients' satisfaction after total knee arthroplasty: Tashkent Medical Academy experience. Orthopaedic Journal of Sports Medicine. 2021;9(6 Suppl 2):2325967121S00194. doi:10.1177/2325967121S00194.

8. Baranovsky AA, Urazovskaya IL, Mansurov DSh, Saiganov SA, Mazurov VI, Tkachenko AN, Mamasoliev BM. Organization of treatment of osteoarthritis of the knee joint. Uzbek Journal of Case Reports. 2022;2(3):37-45. doi:10.55620/ujcr.2.3.2022.5. (In Russ.).